ImmunityBio
Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune SystemCareers
Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.
About Us
ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
Recent News
Dec. 4, 2019
ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superanonist in Non-Muscle Invasive Bladder Cancer
About Us
ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
Careers
Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.
Recent News
Dec. 4, 2019
ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superanonist in Non-Muscle Invasive Bladder Cancer
Contact Us
© 2019 ImmunityBio, Inc. All rights reserved.